These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 28254801)

  • 1. Shifting the Focus of Preclinical, Murine Atherosclerosis Studies From Prevention to Late-Stage Intervention.
    Baylis RA; Gomez D; Owens GK
    Circ Res; 2017 Mar; 120(5):775-777. PubMed ID: 28254801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overview of Therapeutic Approaches for Cholesterol Lowering and Attenuation of Thrombosis for Prevention of Atherothrombosis.
    Weitz JI; Fazio S
    Circ Res; 2019 Feb; 124(3):351-353. PubMed ID: 30702992
    [No Abstract]   [Full Text] [Related]  

  • 3. Future role of proprotein convertase subtilisin/kexin type 9 inhibitors in preventive cardiology.
    Mahmood T; Shapiro MD
    Curr Opin Cardiol; 2019 Sep; 34(5):519-525. PubMed ID: 31246589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-Density Lipoprotein Cholesterol and Drug Treatment to Lower Atherosclerotic Cardiovascular Disease Risk: Where Do We Stand?
    Lloyd-Jones DM
    JAMA Cardiol; 2017 Sep; 2(9):937-938. PubMed ID: 28768306
    [No Abstract]   [Full Text] [Related]  

  • 5. Low-Density Lipoprotein Cholesterol Treatment in the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Era: Getting Back on Target.
    Sabatine MS; Giugliano RP
    JAMA Cardiol; 2017 Sep; 2(9):935-936. PubMed ID: 28768310
    [No Abstract]   [Full Text] [Related]  

  • 6. Reducing cholesterol levels to decrease cardiovascular events: the role of new proprotein convertase subtilisin/kexin type 9 inhibitors.
    Alberto Z
    J Cardiovasc Med (Hagerstown); 2017 Jan; 18 Suppl 1():e184-e186. PubMed ID: 27841824
    [No Abstract]   [Full Text] [Related]  

  • 7. Cholesterol-independent effects of atorvastatin prevent cardiovascular morbidity and mortality in a mouse model of atherosclerotic plaque rupture.
    Roth L; Rombouts M; Schrijvers DM; Martinet W; De Meyer GR
    Vascul Pharmacol; 2016 May; 80():50-8. PubMed ID: 26826559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pleiotropic Anti-atherosclerotic Effects of PCSK9 InhibitorsFrom Molecular Biology to Clinical Translation.
    Karagiannis AD; Liu M; Toth PP; Zhao S; Agrawal DK; Libby P; Chatzizisis YS
    Curr Atheroscler Rep; 2018 Mar; 20(4):20. PubMed ID: 29525934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of proprotein convertase subtilisin/kexin type 9 in the treatment of hypercholesterolemia.
    Ascaso JF
    Endocrinol Nutr; 2016; 63(6):255-7. PubMed ID: 27050861
    [No Abstract]   [Full Text] [Related]  

  • 10. Access to Nonstatin Lipid-Lowering Therapies in Patients at High Risk of Atherosclerotic Cardiovascular Disease.
    Knowles JW; Howard WB; Karayan L; Baum SJ; Wilemon KA; Ballantyne CM; Myers KD
    Circulation; 2017 May; 135(22):2204-2206. PubMed ID: 28446516
    [No Abstract]   [Full Text] [Related]  

  • 11. Emerging Concepts of Vascular Cell Clonal Expansion in Atherosclerosis.
    Misra A; Rehan R; Lin A; Patel S; Fisher EA
    Arterioscler Thromb Vasc Biol; 2022 Mar; 42(3):e74-e84. PubMed ID: 35109671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PCSK9 Inhibitors: From Innovation to Sustainable Clinical Application.
    Lekuona I
    Rev Esp Cardiol (Engl Ed); 2018 Dec; 71(12):996-998. PubMed ID: 30150140
    [No Abstract]   [Full Text] [Related]  

  • 13. Prescribing Patterns of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in Eligible Patients With Clinical Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia.
    Karalis DG; Mallya UG; Ghannam AF; Elassal J; Gupta R; Boklage SH
    Am J Cardiol; 2018 May; 121(10):1155-1161. PubMed ID: 29548678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incorporation of PCSK9 inhibitors into prevention of atherosclerotic cardiovascular disease.
    Wójcik C
    Postgrad Med; 2017 Nov; 129(8):801-810. PubMed ID: 28879791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identifying Vulnerable Atherosclerotic Plaque in Rabbits Using DMSA-USPIO Enhanced Magnetic Resonance Imaging to Investigate the Effect of Atorvastatin.
    Qi C; Deng L; Li D; Wu W; Gong L; Li Y; Zhang Q; Zhang T; Zhang C; Zhang Y
    PLoS One; 2015; 10(5):e0125677. PubMed ID: 25973795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proprotein convertase subtilisin/kexin type 9 inhibitors: New insights into cardiovascular atherosclerotic pathophysiology with therapeutic implications.
    Cokkinos DV; Cokkinos P; Kolovou G
    Arch Cardiovasc Dis; 2019; 112(8-9):455-458. PubMed ID: 31495741
    [No Abstract]   [Full Text] [Related]  

  • 17. What is the role of PCSK9 inhibitors in treating hypercholesterolemia?
    Volpe M
    JAAPA; 2018 Jun; 31(6):14-15. PubMed ID: 29846311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Focus on Cardiovascular prevention].
    Di Pasquale G
    G Ital Cardiol (Rome); 2017; 18(7):531-532. PubMed ID: 28714994
    [No Abstract]   [Full Text] [Related]  

  • 19. The year in cardiology 2015: prevention.
    Chapman MJ; Blankenberg S; Landmesser U
    Eur Heart J; 2016 Feb; 37(6):510-9. PubMed ID: 26726043
    [No Abstract]   [Full Text] [Related]  

  • 20. Inconsistent Guideline Recommendations for Cardiovascular Prevention and the Debate About Zeroing in on and Zeroing LDL-C Levels With PCSK9 Inhibitors.
    Ioannidis JPA
    JAMA; 2017 Aug; 318(5):419-420. PubMed ID: 28738115
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.